Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0200 (3.83%) ($5.0200 - $5.0200) on Tue. Mar. 9, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.1% (three month average) | RSI | 37 | Latest Price | $5.0200(3.83%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1% a day on average for past five trading days. | Weekly Trend | ADMS declines -7.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) BND(62%) IGOV(42%) BWX(41%) JNK(38%) VCIT(38%) | Factors Impacting ADMS price | ADMS will decline at least -2.55% in a week (0% probabilities). EWG(-21%) TBT(-20%) EWI(-19%) EWJ(-17%) XHB(-15%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.55% (StdDev 5.1%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-15.54(-409.56%) | Inflection Point | Yes | Resistance Level | $5.35 | 5 Day Moving Average | $4.84(3.72%) | 10 Day Moving Average | $4.87(3.08%) | 20 Day Moving Average | $5.35(-6.17%) | To recent high | -24.6% | To recent low | 0.4% | Market Cap | $142m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |